Kao WY, et al. - Using data from the Taiwan National Health Insurance Research Database (2003-2013), researchers analyzed the correlation between proton pump inhibitor (PPI) use and hepatocellular carcinoma (HCC) risk. In this analysis, 35,356 patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections were identified. The investigators did not identify any link between a dose-dependent effect of PPI use and HCC risk. The use of PPI was not related to the risk of developing HCC in patients with chronic HBV or HCV infections where the prescription of PPI is tightly regulated, according to findings.